Editas Medicine, Inc.

EDIT

$30.27

+58.09% (1 year change)

Avg closing price

Price range

Market Cap

$2.1 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

Revenue

-

Total revenue in the last quarter.

Net Income

$-23.6 Million

Net income is all revenues minus all expenses including taxes and interest in the last quarter.

Earnings per Share

$-2.52

Earnings per share is the amount of net income that is attributed to each single share outstanding.

Dividends per Share

-

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Price-Earnings Ratio

-13.38x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

EBIT

$-31.3 Million

Earnings before interest expenses and taxes in the last quarter.

Employees

208

The number of full time employees.

Revenue & Earnings

Balance Sheet

Editas Medicine, Inc.

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.

News

Editas Medicine (NASDAQ:EDIT) Stock Price Down 8.8%

Editas Medicine (NASDAQ:EDIT) Stock Price Down 8.8%

Editas Medicine Inc (NASDAQ:EDIT) was down 8.8% on Wednesday . The stock traded as low as $29.85 and last traded at $30.27. Approximately 1,219,194 shares changed hands during mid-day trading, an i...

The Olympia Report The Olympia Report, about 21 hours ago
Usher Syndrome Type 2 Treatment Market Outlook and Forecast Report By ProQR Therapeutics, Editas Medicine, Nobelpharma Co., Ltd, Sensorion, Advanced Bionics AG

Usher Syndrome Type 2 Treatment Market Outlook and Forecast Report By ProQR Therapeutics, Editas Medicine, Nobelpharma Co., Ltd, Sensorion, Advanced Bionics AG

The company profiles of all the key players and brands that are dominating the Usher Syndrome Type 2 Treatment Market have been taken into consideration here. The report has wide-ranging and compre...

OpenPR OpenPR, 22 days ago